Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients.

Derosa G, Putignano P, Bossi AC, Bonaventura A, Querci F, Franzetti IG, Guazzini B, Testori G, Fogari E, Maffioli P

European journal of pharmacology1 Jun 2011Cited by 56 (Europe PMC)

PMID21645507DOI10.1016/j.ejphar.2011.05.051PepBankPUB-21645507

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes treated with metformin, exenatide and glimepiride improved glycemic control similarly.
In plain wordsIn type 2 diabetes treated with metformin, exenatide and glimepiride improved blood glucose control similarly.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeGlycemic control
Study
n = 111
Comparator
glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg twice daily, titrated after 1 month to 10 μg twice daily · 12 monthsAs given in this study (human).
Source sentences
Summary
Both treatments gave a similar improvement of glycemic control, without any differences between the two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
One hundred and eleven patients with uncontrolled type 2 diabetes mellitus and intolerant to metformin at the highest dosages (2500-3000 mg/day) were enrolled in this study.
Summary · context
Patients were randomized to receive exenatide 5 μg twice a day or glimepiride 1mg three times a day and titrated after 1 month to exenatide 10 μg twice a day or glimepiride 2mg three times a day for 12 months in a randomized, single-blind, controlled study.
Report a problemFND-2164550701
02HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, only exenatide reduced BMI, with values significantly better than glimepiride.
In plain wordsIn type 2 diabetes, only exenatide reduced BMI, with better values than glimepiride.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBMI
Study
n = 111
Comparator
glimepiride
Outcome group
Body weight · Metabolic and weight
Studied dose
5 μg twice daily, titrated after 1 month to 10 μg twice daily · 12 monthsAs given in this study (human).
Source sentences
Summary
Only exenatide gave a decrease of BMI, insulin resistance parameters such as fasting plasma insulin, HOMA-IR, and adiponectin and a decrease of inflammatory parameters such as tumor necrosis factor-α, and high sensitivity-C reactive protein.
3 context sentences(design, population, supporting numbers)
Summary · context
Furthermore, the values obtained with exenatide were significantly better than the values recorded with glimepiride.
Summary · context
One hundred and eleven patients with uncontrolled type 2 diabetes mellitus and intolerant to metformin at the highest dosages (2500-3000 mg/day) were enrolled in this study.
Summary · context
Patients were randomized to receive exenatide 5 μg twice a day or glimepiride 1mg three times a day and titrated after 1 month to exenatide 10 μg twice a day or glimepiride 2mg three times a day for 12 months in a randomized, single-blind, controlled study.
Report a problemFND-2164550702
03HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, only exenatide reduced fasting plasma insulin, with values significantly better than glimepiride.
In plain wordsIn type 2 diabetes, only exenatide reduced fasting insulin, with better values than glimepiride.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFasting plasma insulin
Study
n = 111
Comparator
glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg twice daily, titrated after 1 month to 10 μg twice daily · 12 monthsAs given in this study (human).
Source sentences
Summary
Only exenatide gave a decrease of BMI, insulin resistance parameters such as fasting plasma insulin, HOMA-IR, and adiponectin and a decrease of inflammatory parameters such as tumor necrosis factor-α, and high sensitivity-C reactive protein.
3 context sentences(design, population, supporting numbers)
Summary · context
Furthermore, the values obtained with exenatide were significantly better than the values recorded with glimepiride.
Summary · context
One hundred and eleven patients with uncontrolled type 2 diabetes mellitus and intolerant to metformin at the highest dosages (2500-3000 mg/day) were enrolled in this study.
Summary · context
Patients were randomized to receive exenatide 5 μg twice a day or glimepiride 1mg three times a day and titrated after 1 month to exenatide 10 μg twice a day or glimepiride 2mg three times a day for 12 months in a randomized, single-blind, controlled study.
Report a problemFND-2164550703
04HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, only exenatide reduced HOMA-IR, with values significantly better than glimepiride.
In plain wordsIn type 2 diabetes, only exenatide reduced the reported insulin resistance measure, with better values than glimepiride.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHOMA-IR
Study
n = 111
Comparator
glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg twice daily, titrated after 1 month to 10 μg twice daily · 12 monthsAs given in this study (human).
Source sentences
Summary
Only exenatide gave a decrease of BMI, insulin resistance parameters such as fasting plasma insulin, HOMA-IR, and adiponectin and a decrease of inflammatory parameters such as tumor necrosis factor-α, and high sensitivity-C reactive protein.
3 context sentences(design, population, supporting numbers)
Summary · context
Furthermore, the values obtained with exenatide were significantly better than the values recorded with glimepiride.
Summary · context
One hundred and eleven patients with uncontrolled type 2 diabetes mellitus and intolerant to metformin at the highest dosages (2500-3000 mg/day) were enrolled in this study.
Summary · context
Patients were randomized to receive exenatide 5 μg twice a day or glimepiride 1mg three times a day and titrated after 1 month to exenatide 10 μg twice a day or glimepiride 2mg three times a day for 12 months in a randomized, single-blind, controlled study.
Report a problemFND-2164550704
05HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, the results sentence reports decreased adiponectin only with exenatide, although the conclusion describes an increase.
In plain wordsIn type 2 diabetes, the results report lower adiponectin with exenatide, but the conclusion gives the opposite direction.
Peptide
Exenatide (exendin-4)
Outcome
MixedAdiponectin
Study
n = 111
Comparator
glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg twice daily, titrated after 1 month to 10 μg twice daily · 12 monthsAs given in this study (human).
Source sentences
Summary
Only exenatide gave a decrease of BMI, insulin resistance parameters such as fasting plasma insulin, HOMA-IR, and adiponectin and a decrease of inflammatory parameters such as tumor necrosis factor-α, and high sensitivity-C reactive protein.
3 context sentences(design, population, supporting numbers)
Summary · context
Furthermore, adiponectin increase, and tumor necrosis factor-α reduction seem to be related to weight loss obtained with exenatide.
Summary · context
One hundred and eleven patients with uncontrolled type 2 diabetes mellitus and intolerant to metformin at the highest dosages (2500-3000 mg/day) were enrolled in this study.
Summary · context
Patients were randomized to receive exenatide 5 μg twice a day or glimepiride 1mg three times a day and titrated after 1 month to exenatide 10 μg twice a day or glimepiride 2mg three times a day for 12 months in a randomized, single-blind, controlled study.
Report a problemFND-2164550705
06HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, only exenatide reduced tumor necrosis factor-alpha, with values significantly better than glimepiride.
In plain wordsIn type 2 diabetes, only exenatide reduced tumor necrosis factor-alpha, with better values than glimepiride.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTumor necrosis factor-alpha
Study
n = 111
Comparator
glimepiride
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
5 μg twice daily, titrated after 1 month to 10 μg twice daily · 12 monthsAs given in this study (human).
Source sentences
Summary
Only exenatide gave a decrease of BMI, insulin resistance parameters such as fasting plasma insulin, HOMA-IR, and adiponectin and a decrease of inflammatory parameters such as tumor necrosis factor-α, and high sensitivity-C reactive protein.
3 context sentences(design, population, supporting numbers)
Summary · context
Furthermore, the values obtained with exenatide were significantly better than the values recorded with glimepiride.
Summary · context
One hundred and eleven patients with uncontrolled type 2 diabetes mellitus and intolerant to metformin at the highest dosages (2500-3000 mg/day) were enrolled in this study.
Summary · context
Patients were randomized to receive exenatide 5 μg twice a day or glimepiride 1mg three times a day and titrated after 1 month to exenatide 10 μg twice a day or glimepiride 2mg three times a day for 12 months in a randomized, single-blind, controlled study.
Report a problemFND-2164550706
07HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, only exenatide reduced high-sensitivity C-reactive protein, with values significantly better than glimepiride.
In plain wordsIn type 2 diabetes, only exenatide reduced high-sensitivity C-reactive protein, with better values than glimepiride.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHigh-sensitivity C-reactive protein
Study
n = 111
Comparator
glimepiride
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
5 μg twice daily, titrated after 1 month to 10 μg twice daily · 12 monthsAs given in this study (human).
Source sentences
Summary
Only exenatide gave a decrease of BMI, insulin resistance parameters such as fasting plasma insulin, HOMA-IR, and adiponectin and a decrease of inflammatory parameters such as tumor necrosis factor-α, and high sensitivity-C reactive protein.
3 context sentences(design, population, supporting numbers)
Summary · context
Furthermore, the values obtained with exenatide were significantly better than the values recorded with glimepiride.
Summary · context
One hundred and eleven patients with uncontrolled type 2 diabetes mellitus and intolerant to metformin at the highest dosages (2500-3000 mg/day) were enrolled in this study.
Summary · context
Patients were randomized to receive exenatide 5 μg twice a day or glimepiride 1mg three times a day and titrated after 1 month to exenatide 10 μg twice a day or glimepiride 2mg three times a day for 12 months in a randomized, single-blind, controlled study.
Report a problemFND-2164550707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.